Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study

Am J Hematol. 2024 Aug;99(8):1640-1643. doi: 10.1002/ajh.27366. Epub 2024 May 15.

Authors

Jan Philipp Bewersdorf¹, Shai Shimony², Rory M Shallis³, Yiwen Liu⁴, Guillaume Berton⁵, Eva J Schaefer^{2

6}, Amer M Zeidan³, Aaron Goldberg¹, Eytan Stein¹, Guido Marcucci⁷, Rebecca P Bystrom², R Coleman Lindsley², Evan C Chen², Jorge Ramos⁷, Anthony Stein⁷, Vinod Pullarkat⁷, Ibrahim Aldoss⁷, Daniel J DeAngelo², Donna S Neuberg⁴, Richard M Stone², Sylvain Garciaz⁵, Brian Ball⁷, Maximilian Stahl²

Affiliations

¹ Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
² Department of Medical Oncology, Division of Leukemia, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
³ Hematology Section, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut, USA.
⁴ Data Science, Dana Farber Cancer Institute, Boston, Massachusetts, USA.
⁵ Hematology Department, Aix-Marseille Université, Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France.
⁶ Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany.
⁷ Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.

PMID: 38751104
DOI: 10.1002/ajh.27366

No abstract available

Publication types

Multicenter Study
Research Support, N.I.H., Extramural

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Bridged Bicyclo Compounds, Heterocyclic* / administration & dosage
Bridged Bicyclo Compounds, Heterocyclic* / therapeutic use
Cohort Studies
Female
Humans
Induction Chemotherapy*
Isocitrate Dehydrogenase* / antagonists & inhibitors
Isocitrate Dehydrogenase* / genetics
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Male
Middle Aged
Mutation*
Sulfonamides* / administration & dosage
Sulfonamides* / therapeutic use

Substances

Bridged Bicyclo Compounds, Heterocyclic
IDH1 protein, human
IDH2 protein, human
Isocitrate Dehydrogenase
Sulfonamides
venetoclax

Grants and funding